iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

Core Insights - Insight Molecular Diagnostics Inc. has appointed Dr. Nick Ioannou as Vice President of Medical Affairs, bringing extensive experience in organ transplant, nephrology, cardiology, genetics, and oncology [1][5] Company Overview - Insight Molecular Diagnostics is a pioneering diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [6] Dr. Nick Ioannou's Background - Dr. Ioannou has over three decades of experience in clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs, with significant collaboration with key opinion leaders in various therapeutic areas [2] - His previous roles include senior positions at Guardant Health, Natera, LA Ort Institute, L-Nutra, and CSL Behring, among others [3] - He has nearly 10 years of experience as a medical director and partner in private clinics, enhancing his ability to connect with patients and healthcare professionals [4] Strategic Importance of Appointment - The CEO of iMDx, Josh Riggs, emphasized that Dr. Ioannou's expertise is crucial for the company as it prepares to launch its first commercial products in transplant rejection testing [5] - Dr. Ioannou expressed enthusiasm about joining iMDx, highlighting the need for improved transplant rejection testing paradigms [5]